dinoprost and Neuroblastoma

Inhibition of neuronal cyclooxygenase-2 (COX-2) and hence prostaglandin E2 (PGE2) synthesis by non-steroidal anti-inflammatory drugs has been suggested to protect neuronal cells in a variety of pathophysiological situations including Alzheimer's disease and ischemic stroke. Ascorbic acid (vitamin C) has also been shown to protect cerebral tissue in a variety of experimental conditions, which has been attributed to its antioxidant capacity. In the present study, we show that ascorbic acid dose-dependently inhibited interleukin-1beta (IL-1beta)-mediated PGE2 synthesis in the human neuronal cell line, SK-N-SH. Furthermore, in combination with aspirin, ascorbic acid augmented the inhibitory effect of aspirin on PGE2 synthesis. However, ascorbic acid had no synergistic effect along with other COX inhibitors (SC-58125 and indomethacin). The inhibition of IL-1beta-mediated PGE2 synthesis by ascorbic acid was not due to the inhibition of the expression of COX-2 or microsomal prostaglandin E synthase (mPGES-1). Rather, ascorbic acid dose-dependently (0.1-100 microM) produced a significant reduction in IL-1beta-mediated production of 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha), a reliable indicator of free radical formation, suggesting that the effects of ascorbic acid on COX-2-mediated PGE2 biosynthesis may be the result of the maintenance of the neuronal redox status since COX activity is known to be enhanced by oxidative stress. Our results provide in vitro evidence that the neuroprotective effects of ascorbic acid may depend, at least in part, on its ability to reduce neuronal COX-2 activity and PGE2 synthesis, owing to its antioxidant properties. Further, these experiments suggest that a combination of aspirin with ascorbic acid constitutes a novel approach to render COX-2 more sensitive to inhibition by aspirin, allowing an anti-inflammatory therapy with lower doses of aspirin, thereby avoiding the side effects of the usually high dose aspirin treatment.

Topics: Antioxidants; Ascorbic Acid; Aspirin; Blotting, Western; Cell Line, Tumor; Cyclooxygenase 2; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression; Humans; Interleukin-1; Neural Inhibition; Neuroblastoma; Neurons

Topics: Animals; Astrocytes; Cells, Cultured; CHO Cells; Ciliary Body; Cricetinae; Cricetulus; Dinoprost; Dinoprostone; Glaucoma; Humans; Intraocular Pressure; Lens, Crystalline; Models, Biological; Neuroblastoma; Rabbits; Rats; Receptors, Prostaglandin; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured

The accumulation of inositol phosphates (IPs) in response to prostaglandins (PGs) was studied in NG108-15 cells preincubated with myo-[3H]inositol. As a positive control, bradykinin caused accumulation of IPs transiently at an early phase (within 1 min) and continuously during a late phase (15-60 min) of incubation in the cells. PGD2 and PGF2 alpha did not significantly cause the accumulation of IPs at an early phase but significantly stimulated inositol bisphosphate (IP2) and inositol monophosphate (IP) formation at late phase of incubation. The maximum stimulation was obtained at greater than 10(-7) M concentrations of these PGs, the levels being three-and twofold for IP2 and IP1, respectively. 9 alpha, 11 beta-PGF2 has a slight effect but PGE2 and the metabolites of PGD2 and PGF2 alpha have no effect up to 10(-6)M. The effects of PGD2 and PGF2 alpha were not additive, but the effect of each PG was additive to that of bradykinin at a late phase of incubation. Inositol 1-monophosphate was mainly identified in the stimulation by 10(-5) M PGD2 and 10(-5) M PGF2 alpha, whereas both inositol 1-monophosphate and inositol 4-monophosphate were produced in the stimulation by 10(5) M bradykinin. Depletion of extracellular Ca2+ diminished the stimulatory effect of PGD2 and PGF2 alpha and late-phase effect of bradykinin, but simple Ca2+ influx into the cells by high K+, ionomycin, or A23187 failed to cause such late-phase effects. These results suggest that PGD2 and PGF2 alpha specifically stimulate hydrolysis of inositol phospholipids.

Topics: Animals; Bradykinin; Calcium; Chromatography, High Pressure Liquid; Dinoprost; Dose-Response Relationship, Drug; Egtazic Acid; Glioma; Hybrid Cells; Inositol Phosphates; Isomerism; Neuroblastoma; Prostaglandin D2; Stimulation, Chemical; Time Factors; Tumor Cells, Cultured

Various prostaglandins (PGs) (10 nM-30 microM) were added to NG108-15 cells in culture, and changes in the levels of intracellular cyclic GMP and Ca2+ were investigated. Exposure of the cells to PGF2 alpha, PGD2, and PGE2 (10 microM) transiently increased the cyclic GMP content 7.5-, 3.9-, and 3.1-fold, respectively. Furthermore, the increased levels of cyclic GMP correlated well with the rise in cytosolic free Ca2+ concentrations induced by the PGs. Other PGs (10 microM), including metabolites and synthetic analogs, which had no effect on intracellular Ca2+, failed to increase the cyclic GMP content in the cells. When extracellular Ca2+ was depleted from the culture medium, the PG-induced increase in cyclic GMP level was almost completely abolished. In addition, treatment of the cells with quin 2 tetraacetoxymethyl ester dose-dependently inhibited the PG-induced cyclic GMP formation. The increase in cyclic GMP content caused by treatment of the cells with a high K+ level (50 mM) was completely blocked by voltage-dependent Ca2+ entry blockers, such as verapamil (10 microM), nifedipine (1 microM), and diltiazem (100 microM); however, the PG (10 microM)-induced increase in cyclic GMP content was not affected by such Ca2+ entry blockers. These findings indicate that PG-induced cyclic GMP formation may require the rise in intracellular Ca2+ level and that the voltage-dependent Ca2+ channels may not be involved in the PG-induced rise in Ca2+ content.

Topics: Aminoquinolines; Animals; Calcium; Cyclic GMP; Diltiazem; Dinoprost; Dinoprostone; Fluorescent Dyes; Glioma; Hybrid Cells; Kinetics; Mice; Neuroblastoma; Nifedipine; Potassium; Prostaglandin D2; Prostaglandins; Prostaglandins D; Prostaglandins E; Prostaglandins F; Rats; Tumor Cells, Cultured; Verapamil

The cellular cGMP content increased in response to a variety of receptor agonists, which activate [e.g., prostaglandin (PG) E1, E2, and F2 alpha] or inhibit (e.g., alpha-adrenergic, muscarinic, and opiate agonists) adenylate cyclase in neuroblastoma X glioma hybrid NG108-15 cells. The responses were additive when PGF2 alpha and enkephalin were mixed. The inhibitory guanine nucleotide regulatory protein (Ni) is involved in adenylate cyclase inhibition; this function of Ni is lost when it is ADP-ribosylated by islet-activating protein (IAP), pertussis toxin [H. Kurose, T. Katada, T. Amano, and M. Ui (1983) J. Biol. Chem. 258, 4870-4875]. The cGMP rise induced by stimulation of the receptors linked to adenylate cyclase inhibition was also diminished by IAP; the time course and dose response for the IAP-induced diminution were the same between adenylate cyclase inhibition and cGMP generation. Ni thus appears to mediate guanylate cyclase activation as well as adenylate cyclase inhibition initiated via the same receptors. Melittin also increased cGMP. No additivity was shown when enkephalin and melittin were combined, suggesting that phospholipase A2 might play a role in Ni-mediated guanylate cyclase activation. On the other hand, the PGF2 alpha-induced cGMP rise was associated with increased incorporation of 32Pi into phosphatidylinositol; was not affected by cholera toxin, IAP or forskolin; and showed no additivity when combined with A23187, which increased cGMP by itself. PGs would occupy receptors linked to phosphatidylinositol breakdown, thereby increasing the availability of intracellular Ca2+, which is responsible for guanylate cyclase activation. Thus, dual pathways are proposed for a receptor-mediated cGMP rise in NG108-15 cells.

Topics: Adenylate Cyclase Toxin; Animals; Bacterial Toxins; Calcimycin; Cyclic AMP; Cyclic GMP; Dinoprost; Enkephalins; Glioma; Hybrid Cells; Melitten; Mice; Neuroblastoma; Pertussis Toxin; Phospholipids; Prostaglandins F; Rats; Receptors, Cell Surface; Virulence Factors, Bordetella

The effect of prostaglandin (PG) D2 on neuronal functions was investigated in neuroblastoma X glioma NG108-15 hybrid cells. PGD2 caused a sustained increase in miniature end-plate potentials (MEPPs) recorded from cultured striated muscle cells which had formed junctions with NG108-15 cells. PGD2 initially hyperpolarized and then depolarized NG108-15 cells. The time course of depolarization fitted well to the facilitative phase of MEPPs. The same action on synaptic transmission and membrane potentials was detected with PGF2 alpha but not with PGE1. PGD2 (10(-4)M) produced a 3-fold increase of adenylate cyclase activity in NG108-15 cell homogenates through its receptors that are distinct from those of PGE1 and PGI2. These results show that PGD2 facilitates MEPP frequency from NG108-15 cells due to depolarization, and suggest that PGD2 may act as a physiological neuromodulator for synaptic transmission in vivo.

Topics: Adenylyl Cyclases; Alprostadil; Animals; Cell Line; Dinoprost; Epoprostenol; Glioma; Hybrid Cells; Kinetics; Membrane Potentials; Mice; Muscles; Neuroblastoma; Prostaglandin D2; Prostaglandins D; Prostaglandins E; Prostaglandins F; Rats; Synapses; Synaptic Transmission

The cytotoxic action of prostaglandin (PG) D2, E1 and F2 alpha was examined on human neuroblastoma cells (NB-1 cell line), and PGD2 was found to be the most effective. PGE1, thought to be the most effective among all PGs in the therapy of neuroblastoma, was much less effective than PGD2. PGF2 alpha did not show any inhibitory effect on the proliferation of NB-1 cells. When PGD2 was added, the cytoplasma became microscopically larger, then the cells gradually died off. PGD2 also exerted a dose-dependent inhibition of DNA and RNA syntheses. These results strongly suggest an antineoplastic activity of PGD2 for human neuroblastoma.

Topics: Alprostadil; Cell Division; Cell Line; Cell Survival; Dinoprost; DNA Replication; Humans; Kinetics; Neuroblastoma; Prostaglandin D2; Prostaglandins; Prostaglandins D; Prostaglandins E; Prostaglandins F; Structure-Activity Relationship; Transcription, Genetic